Springboard Corner: June 2022

Jun 15, 2022


Welcome To The Springboard Corner

It’s been an impressive six months for Springboard companies so far, and this Springboard Corner wraps up the first half of 2022. The Springboard Corner is designed to highlight and share recent milestones of life science and hi-tech startups which we have worked with through Connect’s Springboard program.

Here’s the latest from Connect’s Springboard companies!

Avacen Medical – was founded in 2009 and has developed a drug-free, noninvasive and FDA-cleared medical device for chronic pain management associated with various diseases.They recently received two recognition awards by California State Treasurer, the Honorable Fiona Ma, for advancing medical science.

Biolinq – founded in 2012, Biolinq develops wearable devices that use minimally-invasive microarrays of electrochemical sensors to continuously monitor various biomarkers. They recently closed their $115.8M Series B round with plans to receive regulatory clearance of their glucose sensor patch and launch into the marketplace. 

GroupSolver – a market research technology company which leads in the development of innovative survey tools using AI, they recently raised a $2.5M round. They plan to continue expansion of their product offerings and accelerate growing their market share.  

Independa – following on their secured partnership with LG earlier this year, Independa continues to expand its innovative health offerings to help older adults remain engaged and well taken care of. Their Independa Health Hub®, which integrates with LG smart TVs, now offers mental telehealthcare, at home lab tests, and several other resources. 

Novomedix – an early-stage biotech founded in 2001, the company focuses on developing novel small molecules targeting cancer and fibrosis. They recently received a $2M SBIR Ph-2 grant from the National Heart, Lung and Blood Institute Division of the NIH to advance the development of their first-in-class drug candidate to treat Triple-Negative Breast Cancer.

We look forward to what the second half of 2022 brings!